


DEAV2002/0050 US NP

We claim:

1. (currently amended) A compound of the formula I,



I

wherein

- R1 and R2 are each independently H, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or (C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl is optionally substituted by OH, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>4</sub>)-alkyl or N[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>;
- R3 and R4 are each independently F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl or (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl and (C<sub>2</sub>-C<sub>6</sub>)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;
- R5 is H, F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl or (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl and (C<sub>2</sub>-C<sub>6</sub>)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

DEAV2002/0050 US NP

A is H, F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S(O)<sub>1,2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl-, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> or NHCOR<sub>6</sub>, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S(O)<sub>1,2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl-, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, SO<sub>2</sub>NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl and SO<sub>2</sub>N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> are optionally mono- or polysubstituted by F, Cl, Br, COOH, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> or OCO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;

R<sub>6</sub> is H, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>4</sub>)-alkylene, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-CONH<sub>2</sub>, (C<sub>6</sub>-C<sub>10</sub>)-aryl, (C<sub>1</sub>-C<sub>4</sub>)-alkylene-(C<sub>6</sub>-C<sub>10</sub>)-aryl, heteroaryl, (C<sub>1</sub>-C<sub>4</sub>)-alkylene-heteroaryl or CO-heteroaryl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>4</sub>)-alkylene, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH and (C<sub>1</sub>-C<sub>6</sub>)-alkylene-CONH<sub>2</sub> are optionally mono- or polysubstituted by F, Cl, Br, O(C<sub>1</sub>-C<sub>4</sub>-alkyl), COO-(C<sub>1</sub>-C<sub>4</sub>-alkyl) or N-[(C<sub>1</sub>-C<sub>4</sub>)-alkyl]<sub>2</sub> and said (C<sub>6</sub>-C<sub>10</sub>)-aryl, (C<sub>1</sub>-C<sub>4</sub>)-alkylene-(C<sub>6</sub>-C<sub>10</sub>)-aryl, heteroaryl, (C<sub>1</sub>-C<sub>4</sub>)-alkylene-heteroaryl and CO-heteroaryl are optionally mono- or polysubstituted by F, Cl, Br, NO<sub>2</sub>, CN, O-(C<sub>1</sub>-C<sub>4</sub>-alkyl), S-COO(C<sub>1</sub>-C<sub>4</sub>-alkyl), COO-(C<sub>1</sub>-C<sub>4</sub>-alkyl), N-[(C<sub>1</sub>-C<sub>4</sub>)-alkyl]<sub>2</sub> or (C<sub>1</sub>-C<sub>6</sub>)-alkyl;

n is 0, 1, 2 or 3;

DEAV2002/0050 US NP

m is 1, 2, 3, 4 or 5;

o is 0, 1, 2 or 3;

Het is a heterocyclic 4- to 7-membered ring which may contain up to four N, O or S heteroatoms and wherein said heterocyclic 4- to 7-membered ring is optionally substituted by R7, R8 and R9, with the proviso that said heterocyclic 4- to 7-membered ring cannot be pyrrole; and

R7, R8, and R9 are each independently H, F, Cl, Br, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, OH, oxo, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, COOH, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-aryl or (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-aryl and (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl are optionally substituted by COOH, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, OCO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, F, Cl, (C<sub>1</sub>-C<sub>6</sub>)-alkyl or O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl; and two radicals selected from said R7, R8 and R9 may optionally be bonded together to form a ring fused onto said heterocyclic 4- to 7-membered ring;

and pharmaceutically acceptable salts thereof.

2. (currently amended) The compound of Claim 1 wherein

R1 and R2 are H;

R3 and R4 are each independently F, Cl or Br;

DEAV2002/0050 US NP

- R5 is H, F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl or (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl and (C<sub>2</sub>-C<sub>6</sub>)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;
- A is H, F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S(O)<sub>1-2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl-, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> or NHCOR<sub>6</sub>, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S(O)<sub>1-2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl-, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, SO<sub>2</sub>NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl and SO<sub>2</sub>N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> are optionally mono- or polysubstituted by F, Cl, Br, COOH, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> or OCO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;
- R6 is H, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>4</sub>)-alkylene, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-CONH<sub>2</sub>, (C<sub>6</sub>-C<sub>10</sub>)-aryl, (C<sub>1</sub>-C<sub>4</sub>)-alkylene-(C<sub>6</sub>-C<sub>10</sub>)-aryl, heteroaryl, (C<sub>1</sub>-C<sub>4</sub>)-alkylene-heteroaryl or CO-heteroaryl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)-cycloalkyl-(C<sub>1</sub>-C<sub>4</sub>)-alkylene, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH and (C<sub>1</sub>-C<sub>6</sub>)-

DEAV2002/0050 US NP


alkylene-CONH<sub>2</sub> are optionally mono- or polysubstituted by F, Cl, Br, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, or N-[(C<sub>1</sub>-C<sub>4</sub>)-alkyl]<sub>2</sub>, and said (C<sub>6</sub>-C<sub>10</sub>)-aryl, (C<sub>1</sub>-C<sub>4</sub>)-alkylene-(C<sub>6</sub>-C<sub>10</sub>)-aryl, heteroaryl, (C<sub>1</sub>-C<sub>4</sub>)-alkylene-heteroaryl and CO-heteroaryl are optionally mono- or polysubstituted by F, Cl, Br, NO<sub>2</sub>, CN, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, S-COO-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>4</sub>)-alkyl]<sub>2</sub> or (C<sub>1</sub>-C<sub>6</sub>)-alkyl;

n is 0, 1 or 2;

m is 1;

o is 0 or 1;

Het is a heterocyclic 4- to 7-membered ring selected from triazolyl, tetrazolyl, oxadiazolyl, pyrazolyl, benzimidazolyl, furyl, triazinyl or



wherein said heterocyclic 4- to 7-membered ring is optionally substituted by R7, R8 and R9; and

R7, R8, and R9 are each independently H, F, Cl, Br, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, OH, oxo, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, COOH, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-aryl or (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-aryl and (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl are optionally substituted by COOH, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, OCO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, F, Cl, (C<sub>1</sub>-C<sub>6</sub>)-alkyl or O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;

DEAV2002/0050 US NP

and two radicals selected from said R7, R8 and R9 may optionally be bonded together to form a ring fused onto said heterocyclic 4- to 7-membered ring;

and pharmaceutically acceptable salts thereof.

3. (currently amended) The compound of Claim 2 wherein

R1 and R2 are H;

R3 and R4 are each independently F, Cl or Br;

R5 is H, F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl or (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl and (C<sub>2</sub>-C<sub>6</sub>)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;

A is H, F, Cl, Br, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, CN, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;


n is 0, 1 or 2;

m is 1;

o is 0 or 1;

DEAV2002/0050 US NP


Het is a heterocyclic 4- to 7-membered ring group selected from triazolyl,

tetrazolyl, oxadiazolyl, furyl, triazinyl or , wherein said 4- to 7-membered heterocyclic ring is optionally substituted by R7, R8 and R9; and

R7, R8, and R9 are each independently H, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, OH, oxo, NH<sub>2</sub>, COOH, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl and CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> are optionally substituted by COOH;

and pharmaceutically acceptable salts thereof.

4. (currently amended) The compound of Claim 1 wherein the compound has the structure Ia



Ia

wherein


R5 is H, F, Cl, Br, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, CN, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;

DEAV2002/0050 US NP

- A is H, F, Cl, Br, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CF<sub>3</sub>, OCF<sub>3</sub>, NO<sub>2</sub>, CN, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;
- R7 is H, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-aryl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl or O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-aryl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl and O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;
- R8 is -(C=O)-X;
- X is OH, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or N-((C<sub>1</sub>-C<sub>6</sub>)-alkyl)<sub>2</sub>;
- m is 1 or 2; and
- n is 1 or 2;

and pharmaceutically acceptable salts thereof.

5. (previously amended) The compound of Claim 1 wherein the compound has the structure Ia



Ia

DEAV2002/0050 US NP

wherein

R5 is H or F;

A is H, F, Cl, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CF<sub>3</sub>, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, or SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;

R7 is H or phenyl;

R8 is -(C=O)-X; and

X is OH, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>;

and pharmaceutically acceptable salts thereof.

6. (original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of Claim 1.

7. (previously amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of Claim 1 and at least one further active ingredient.

8. (withdrawn) The pharmaceutical composition of Claim 7, wherein said further active ingredient is selected from the group consisting of:  
antidiabetics, hypoglycemic active ingredients, HMG-CoA reductase inhibitors, cholesterol absorption inhibitors, PPAR gamma agonists, PPAR alpha agonists, PPAR alpha/gamma agonists, fibrates, MTP inhibitors, bile acid absorption inhibitors, CETP inhibitors, polymeric bile acid adsorbents, LDL receptor inducers, ACAT inhibitors, antioxidants, lipoprotein lipase inhibitors, ATP-citrate-lyase inhibitors, squalene synthetase inhibitors, lipoprotein(a) antagonists, lipase inhibitors, insulins, sulfonylureas, biguanides, meglitinides, thiazolidinediones,  $\alpha$ -glucosidase inhibitors, active ingredients acting on the ATP-dependent potassium channel of the beta cells, CART agonists, NPY

DEAV2002/0050 US NP

agonists, MC4 agonists, orexin agonists, H3 agonists, TNF agonists, CRF agonists, CRF BP antagonists, urocortin agonists,  $\beta 3$  agonists, MSH (melanocyte-stimulating hormone) agonists, CCK agonists, serotonin reuptake inhibitors, mixed serotonergic and noradrenergic compounds, 5HT agonists, bombesin agonists, galanin antagonists, growth hormones, growth hormone-releasing compounds, TRH agonists, uncoupling protein 2 or 3 modulators, leptin agonists, DA agonists (bromocriptine, Doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators or TR- $\beta$  agonists or amphetamines.

9. (original) A method of reducing blood sugar comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

10. (original) A method for treating lipid and carbohydrate metabolism disorders comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.


11. (original) A method for treating type 2 diabetes comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

12. (original) A method for treating arteriosclerotic symptoms comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

13. (original) A method for treating insulin resistance comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Claim 1.

14. (currently amended) A process for preparing a compound of Claim 1, which comprises reacting a urea of formula 2 with a compound of formula 4

DEAV2002/0050 US NP



wherein

- R1 and R2** are each independently H, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or (C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl is optionally substituted by OH, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>4</sub>)-alkyl or N[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>;
- R3 and R4** are each independently F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl or (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl and (C<sub>2</sub>-C<sub>6</sub>)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;
- R5** is H, F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl or (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl and (C<sub>2</sub>-C<sub>6</sub>)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;
- A** is H, F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S(O)<sub>1-2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl-, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NH-(C<sub>1</sub>-C<sub>6</sub>)-


DEAV2002/0050 US NP

alkyl,  $\text{SO}_2\text{N}[(\text{C}_1\text{-C}_6)\text{-alkyl}]_2$  or  $\text{NHCOR}_6$ , wherein said  $(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{CO}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $(\text{C}_1\text{-C}_6)\text{-alkylene-COOH}$ ,  $(\text{C}_1\text{-C}_6)\text{-alkylene-COO}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{SO}_2(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $(\text{C}_2\text{-C}_6)\text{-alkenyl}$ ,  $(\text{C}_2\text{-C}_6)\text{-alkynyl}$ ,  $\text{O}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{S}(\text{O})_{1,2}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{NH}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{N}[(\text{C}_1\text{-C}_6)\text{-alkyl}]_2$ ,  $\text{COO}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{CONH}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{CON}[(\text{C}_1\text{-C}_6)\text{-alkyl}]_2$ ,  $\text{SO}_2\text{NH}(\text{C}_1\text{-C}_6)\text{-alkyl}$  and  $\text{SO}_2\text{N}[(\text{C}_1\text{-C}_6)\text{-alkyl}]_2$  are optionally mono- or polysubstituted by F, Cl, Br, COOH,  $\text{COO}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{CONH}_2$ ,  $\text{CONH}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{CON}[(\text{C}_1\text{-C}_6)\text{-alkyl}]_2$  or  $\text{OCO}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ;

n is 0, 1, 2 or 3;


R7 and R8 are each independently H, F, Cl, Br,  $(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{O}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{O}(\text{C}_2\text{-C}_6)\text{-alkenyl}$ ,  $\text{O}(\text{C}_2\text{-C}_6)\text{-alkynyl}$ , OH, oxo,  $\text{O}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{NH}_2$ ,  $\text{NH}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{N}[(\text{C}_1\text{-C}_6)\text{-alkyl}]_2$ ,  $\text{COOH}$ ,  $\text{CO}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{COO}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{CONH}_2$ ,  $\text{CONH}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{CON}[(\text{C}_1\text{-C}_6)\text{-alkyl}]_2$ ,  $(\text{C}_0\text{-C}_6)\text{-alkylene-aryl}$  or  $(\text{C}_1\text{-C}_6)\text{-alkylene-COO}(\text{C}_1\text{-C}_6)\text{-alkyl}$ , wherein said  $(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{O}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{O}(\text{C}_2\text{-C}_6)\text{-alkenyl}$ ,  $\text{O}(\text{C}_2\text{-C}_6)\text{-alkynyl}$ ,  $\text{O}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{NH}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{N}[(\text{C}_1\text{-C}_6)\text{-alkyl}]_2$ ,  $\text{CO}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{COO}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{CONH}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{CON}[(\text{C}_1\text{-C}_6)\text{-alkyl}]_2$ ,  $(\text{C}_0\text{-C}_6)\text{-alkylene-aryl}$  and  $(\text{C}_1\text{-C}_6)\text{-alkylene-COO}(\text{C}_1\text{-C}_6)\text{-alkyl}$  are optionally substituted by  $\text{COOH}$ ,  $\text{CONH}_2$ ,  $\text{CONH}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ,  $\text{CON}[(\text{C}_1\text{-C}_6)\text{-alkyl}]_2$ ,  $\text{OCO}(\text{C}_1\text{-C}_6)\text{-alkyl}$ , F, Cl,  $(\text{C}_1\text{-C}_6)\text{-alkyl}$  or  $\text{O}(\text{C}_1\text{-C}_6)\text{-alkyl}$ ; and said R7 and R8 may optionally be bonded together to form a ring fused onto said heterocyclic 4- to 7-membered ring; and

Y is Cl or



DEAV2002/0050 US NP

15. (currently amended) A process for preparing a compound of Claim 1, which comprises reacting an aniline derivative of formula 3 with a compound of formula 4



wherein

- R2 is H, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl or (C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl is optionally substituted by OH, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, NH<sub>2</sub>, NH(C<sub>1</sub>-C<sub>4</sub>)-alkyl or N[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>;
- R3 and R4 are each independently F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl or (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl and (C<sub>2</sub>-C<sub>6</sub>)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;
- R5 is H, F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl or (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl and (C<sub>2</sub>-C<sub>6</sub>)-alkynyl are optionally mono- or polysubstituted by F, Cl or Br;
- A is H, F, Cl, Br, OH, NO<sub>2</sub>, CN, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl,

DEAV2002/0050 US NP

(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S(O)<sub>1,2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl-, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> or NHCOR<sub>6</sub>, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COOH, (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO(C<sub>1</sub>-C<sub>6</sub>)-alkyl, SO<sub>2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, (C<sub>2</sub>-C<sub>6</sub>)-alkenyl, (C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, S(O)<sub>1,2</sub>-(C<sub>1</sub>-C<sub>6</sub>)-alkyl-, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, SO<sub>2</sub>NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl and SO<sub>2</sub>N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> are optionally mono- or polysubstituted by F, Cl, Br, COOH, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub> or OCO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl;

n is 0, 1, 2 or 3;

R<sub>7</sub> and R<sub>8</sub> are each independently H, F, Cl, Br, (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, OH, oxo, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH<sub>2</sub>, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, COOH, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-aryl or (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, wherein said (C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkenyl, O-(C<sub>2</sub>-C<sub>6</sub>)-alkynyl, O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, NH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, N-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, CO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, (C<sub>0</sub>-C<sub>6</sub>)-alkylene-aryl and (C<sub>1</sub>-C<sub>6</sub>)-alkylene-COO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl are optionally substituted by COOH, CONH<sub>2</sub>, CONH-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, CON-[(C<sub>1</sub>-C<sub>6</sub>)-alkyl]<sub>2</sub>, OCO-(C<sub>1</sub>-C<sub>6</sub>)-alkyl, F, Cl, (C<sub>1</sub>-C<sub>6</sub>)-alkyl or O-(C<sub>1</sub>-C<sub>6</sub>)-alkyl; and said R<sub>7</sub> and R<sub>8</sub> may optionally be bonded together to form a ring fused onto said heterocyclic 4- to 7-membered ring; and

Y is -N=C=O.

16. (New) A compound which is 1-{2-[3-(2-chloro-4,5-difluorobenzoyl)ureido]-4-fluorophenyl}piperidine-4-carboxylic acid and pharmaceutically acceptable salts thereof.